SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) had its price target hoisted by HC Wainwright from $94.00 to $103.00 in a report published on Monday morning, The Fly reports. They currently have a buy rating on the stock.

Other equities analysts have also issued reports about the company. Wedbush set a $53.00 target price on SpringWorks Therapeutics in a research note on Monday, June 20th. The Goldman Sachs Group dropped their target price on SpringWorks Therapeutics from $92.00 to $76.00 and set a buy rating for the company in a research note on Tuesday, May 24th.

SpringWorks Therapeutics Stock Up 12.8 %

NASDAQ SWTX opened at $31.98 on Monday. SpringWorks Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $77.70. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -6.86 and a beta of 0.85. The business has a fifty day moving average of $28.97 and a 200-day moving average of $37.75.

Institutional Investors Weigh In On SpringWorks Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Amundi purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $77,000. Legal & General Group Plc grew its position in SpringWorks Therapeutics by 30.6% during the second quarter. Legal & General Group Plc now owns 28,429 shares of the company's stock valued at $700,000 after acquiring an additional 6,660 shares during the period. ExodusPoint Capital Management LP purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $663,000. Walleye Capital LLC purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $1,624,000. Finally, Goldman Sachs Group Inc. grew its position in SpringWorks Therapeutics by 21.5% during the second quarter. Goldman Sachs Group Inc. now owns 270,687 shares of the company's stock valued at $6,665,000 after acquiring an additional 47,978 shares during the period.

About SpringWorks Therapeutics

(Get Rating)

SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.

Featured Articles

• Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
• Do These Dividend Achievers Deserve A Place In Your Portfolio?
• Darden Restaurants Takes the Low Road Against Inflation
• Why These 3 Stocks Are Off to Hot September Starts
• Inflation Doesn't Differentiate, But it's Impact Does
• 3 Downgraded Must-Have Stocks To Put On Your Watchlist

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.